Moderna stock heads for its highest close since 2023 after CEO Stéphane Bancel says the drugmaker ‘has never been’ just a ...

Moderna (NASDAQ:MRNA) executives emphasized the company’s evolution beyond COVID-19 vaccines during a discussion with ...

Moderna, Inc. MRNA shares are trending on Thursday night. Shares of the Massachusetts-based biotechnology and pharmaceutical company edged 0.087% higher to $194.99 in after-hours trading on Thursday.

Sanofi (Nasdaq: SNY) deprioritized its mRNA flu shot effort. But it is still vigorously defending its substantial share of the flu vaccine market, with its egg-grown Fluzone products and egg-free ...

But what has the stock done for shareholders lately? How has it done over the past five years? Not so great. It has averaged annual losses over that period -- enough to turn a single $10,000 ...

A coveted Presidential Symposium slot at Europe's top oncology congress just sent Moderna shares flying 9%, but the actual ...

Phase 3 data for intismeran autogene in the adjuvant treatment of patients with resected stage IIB-IV melanoma selected ...

After years of layoffs, cash burn and political attacks on its core technology, Moderna’s melanoma vaccine data notched the biotech company a much-needed win.

Moderna (MRNA) reached a 52-week high as CEO Bancel emphasized the company's mRNA platform capabilities beyond COVID vaccines, spotlighting cancer treatment.

Moderna built an artificial intelligence that reads a patient’s tumor and decides what that patient’s medicine should be.

A cancer vaccine developed by Merck and Moderna treating patients with melanoma showed positive and promising late-stage testing results.

Moderna (MRNA) stock hit a 52-week high after CEO Bancel said the company is an mRNA platform, not just a Covid vaccine maker ...